| __timestamp | Arrowhead Pharmaceuticals, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 20707000 |
| Thursday, January 1, 2015 | 57410147 | 17831000 |
| Friday, January 1, 2016 | 41454452 | 18047000 |
| Sunday, January 1, 2017 | 31690298 | 11033000 |
| Monday, January 1, 2018 | 52968505 | 13432000 |
| Tuesday, January 1, 2019 | 81048686 | 52072000 |
| Wednesday, January 1, 2020 | 128874979 | 51488000 |
| Friday, January 1, 2021 | 206342000 | 85727000 |
| Saturday, January 1, 2022 | 297307000 | 95518000 |
| Sunday, January 1, 2023 | 353188000 | 125046000 |
| Monday, January 1, 2024 | 505870000 |
Igniting the spark of knowledge
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Arrowhead Pharmaceuticals, Inc. and Geron Corporation have demonstrated contrasting strategies in their R&D investments.
Arrowhead Pharmaceuticals has shown a remarkable upward trend, with R&D expenses increasing by over 2,000% from 2014 to 2023. This surge reflects their aggressive pursuit of cutting-edge therapies. In contrast, Geron Corporation's R&D spending has grown at a more modest pace, with a 500% increase over the same period.
The data reveals a significant gap in 2024, where Arrowhead's R&D expenses are projected to reach new heights, while Geron's data remains unavailable. This missing data suggests potential strategic shifts or reporting delays. As the biopharmaceutical landscape evolves, these spending patterns offer valuable insights into each company's future trajectory.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Arrowhead Pharmaceuticals, Inc.
R&D Insights: How GSK plc and Geron Corporation Allocate Funds
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Geron Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.
Analyzing R&D Budgets: Grifols, S.A. vs Geron Corporation
Analyzing R&D Budgets: Veracyte, Inc. vs Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Geron Corporation
Research and Development: Comparing Key Metrics for Bausch Health Companies Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Arrowhead Pharmaceuticals, Inc. and Novavax, Inc.
R&D Spending Showdown: Geron Corporation vs Evotec SE